![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1345417
¼¼°èÀÇ ±¤°£¼·´ÜÃþÃÔ¿µ±â ½ÃÀå(2023-2030³â)Global Optical Coherence Tomography Market - 2023-2030 |
°³¿ä
±¤°£¼·´ÜÃþÃÔ¿µ±â(OCT, Optical Coherence Tomography) ½ÃÀåÀº 2022³â¿¡ 15¾ï ´Þ·¯¿¡¼, 2023³âºÎÅÍ 2030³â¿¡ °ÉÃÄ CAGR 8.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 28¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
±¤°£¼·´ÜÃþÃÔ¿µ±â´Â ºûÀ» Ȱ¿ëÇÏ¿© ¹ÌÅ©·Ð ´ÜÀ§ÀÇ Á¶Á÷ ¹è¿À» ÇöÀå¿¡¼ ½Ç½Ã°£À¸·Î ´Ü¸é À̹ÌÁöÈÇÕ´Ï´Ù. ±¤ÇÐ »ý°ËÀ» ¼öÇàÇÏ´Â µ¥ »ç¿ëµÇ´Â ºñħ½ÀÀû À̹Ì¡ ÀýÂ÷ÀÔ´Ï´Ù. ±âÁ¸ÀÇ À̹Ì¡ Á¢±Ù¹ýÀ» Ȱ¿ëÇÒ ¼ö ¾ø´Â ºÎÀ§¿¡ »ç¿ëµË´Ï´Ù. OCT´Â ±¤¼¶À¯¸¦ ±â¹ÝÀ¸·Î Çϸç Ä«Å×ÅÍ, º¹°°æ, ³»½Ã°æ, ¼ö¼ú¿ë ÇÁ·Îºê¿Í °°Àº µµ±¸¿Í °áÇÕÇÏ¿© ½ÅüÀÇ À̹Ì¡À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.
À¯¸®Ã¼¸Á¸·Àå¾Ö °ü¸®¿¡¼ ¾È°úÀû °Ë»ç¿¡ ºñÇØ OCTÀÇ Áß¿äÇÑ ÀåÁ¡Àº À¯¸®Ã¼, ¸Á¸·, ¸Á¸·¿Ü¸· »çÀÌÀÇ 3Â÷¿øÀû ¿¬°ü¼ºÀ» ÇÑÁ¤ÇÒ ¼ö ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. Ȳ¹Ý¿ø°ø, Ȳ¹ÝºÎÁ¾, Ȳ¹ÝÁÖ¸§, ³ì³»Àå, ¿¬·É °ü·Ã Ȳ¹Ýº¯¼º, Á᫐ Àå¾×¼º ¸Á¸·º´Áõ, À¯¸®Ã¼ °ßÀÎ, ´ç´¢¸Á¸·º´Áõ µî ´Ù¾çÇÑ ¾ÈÁúȯÀÇ Áø´Ü¿¡ OCT°¡ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ÇöÀç OCT´Â ½ÉÇ÷°ü Áúȯ, ºñÈæ»öÁ¾ ÇǺξÏ, Àü¸³¼±¾Ï, ¿¬·É °ü·Ã Ȳ¹Ý Áúȯ µî ´Ù¸¥ Ãß°¡ ÁúȯÀÇ ¹ß°ß ¹× Áø´Ü¿¡µµ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.
±¤°£¼·´ÜÃþÃÔ¿µ±â´Â ÁÖ·Î ¾È°ú ÁúȯÀÇ Áõ°¡, ÇÕº´, Àμö ¹× Á¦Ç° Ãâ½Ã¸¦ Æ÷ÇÔÇÑ ½ÃÀå °³¹ß Áõ°¡¿¡ ÀÇÇØ ÃËÁøµË´Ï´Ù. ¶ÇÇÑ, ¾È°ú Áúȯ¿¡ ´ëÇÑ ÀνÄÀ» È®»ê½ÃŰ·Á´Â ³ë·ÂÀÌ Áõ°¡ÇÏ°í ½ÉÇ÷°ü Áúȯ, ºñÈæ»öÁ¾ ÇǺξÏ, Àü¸³¼± ¾Ï ¹× ¿¬·É °ü·Ã Ȳ¹Ý ÁúȯÀ» Æ÷ÇÔÇÑ ±âŸ ¸¸¼º ÁúȯÀÇ »ç·Ê°¡ Áõ°¡ÇÏ´Â °Íµµ ¿¹Ãø ±â°£ µ¿¾È ±Û·Î¹ú ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
¿ªÇÐ
¾È°ú ÁúȯÀÇ Áõ·Ê Áõ°¡
µ¹ÀÌų ¼ö ¾ø´Â ½Ç¸íÀ» À¯¹ßÇÏ´Â ÁøÇ༺ ½Ã½Å°æ º´ÁõÀÎ ³ì³»ÀåÀÇ Áø´Ü°ú °ü¸®¸¦ À§Çؼ´Â Á¶±â ¹ß°ß°ú ¸ð´ÏÅ͸µÀÌ ÇʼöÀûÀÔ´Ï´Ù. ±¤°£¼·´ÜÃþÃÔ¿µ±â(OCT)Àº ³ì³»ÀåÀÇ ±¸Á¶Àû ¾Çȸ¦ °¨ÁöÇÏ°í ¸ð´ÏÅ͸µÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â ¿µ»ó °Ë»ç·Î ¹ßÀüÇØ ¿Ô½À´Ï´Ù. µû¶ó¼ ´ç´¢º´ ¼º ¸Á¸·ÁõÀÇ ³ôÀº À¯º´·üÀº ¿¹Ãø ±â°£ µ¿¾È ±Û·Î¹ú ½ÃÀå ¼ºÀåÀ» ÃËÁø ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, ´ç´¢º´ ¼º ¸Á¸·ÁõÀº Ç÷Áß °íÇ÷´ç ¼öÄ¡·Î ÀÎÇÑ ´«ÀÇ ¸Á¸· ¼Õ»ó°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ÀÌ´Â ´ç´¢º´ÀÇ ¿¹»óµÇ´Â º¹À⼺À¸·Î, Á¦ 1Çü ¹× Á¦ 2Çü ´ç´¢º´À» ¾Î°íÀÖ´Â ¼ö¹é¸¸ ¸íÀÇ °³Àο¡°Ô ¿µÇâÀ» ¹ÌĨ´Ï´Ù.
¶ÇÇÑ, ´Ù¸¥ ¾È°ú ÁúȯÀÇ Áõ°¡ »ç·Êµµ ¿¹Ãø ±â°£ µ¿¾È ±Û·Î¹ú ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, WHO 2023¿¡ µû¸£¸é Àü ¼¼°èÀûÀ¸·Î ÃÖ¼Ò 22¾ï ¸í ÀÌ»óÀÇ »ç¶÷µéÀÌ ±Ù°Å¸® ¶Ç´Â ¿ø°Å¸® ½Ã·Â Àå¾Ö¸¦ °Þ°í ÀÖÀ¸¸ç, ÀÌ Áß ¾à 10¾ï ¸íÀÇ ½Ã·Â Àå¾Ö´Â ¿¹¹æÇÒ ¼ö ÀÖ¾ú°Å³ª ¾ÆÁ÷ Ä¡·áµÇÁö ¾ÊÀº °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ´Ù±¹Àû ¼öÁØ¿¡¼ ½Ã·Â Àå¾Ö¿Í ½Ç¸íÀÇ °¡Àå Å« ¿øÀÎÀº ±¼Àý Àå¾Ö¿Í ¹é³»ÀåÀÔ´Ï´Ù.
10¾ï ¸í¿¡ ´ÞÇÏ´Â Àα¸ Áß ¿ø°Å¸® ½Ã·Â Àå¾Ö ¶Ç´Â ½Ç¸íÀ» À¯¹ßÇÏ´Â ÁÖ¿ä ÁúȯÀ¸·Î´Â 9,400¸¸ ¸í ÀÌ»óÀÇ ¹é³»Àå, ¾à 8,840¸¸ ¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡´Â ±¼Àý ÀÌ»ó, 800¸¸ ¸í ÀÌ»óÀÇ ¿¬·É °ü·Ã Ȳ¹Ýº¯¼º, ¾à 770¸¸ ¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡´Â ³ì³»Àå, 390¸¸ ¸í ÀÌ»óÀÇ ´ç´¢º´¼º ¸Á¸·Áõ µîÀÌ ÀÖ½À´Ï´Ù. ±Ù°Å¸® ½Ã·Â Àå¾Ö¸¦ À¯¹ßÇÏ´Â ÁÖ¿ä ÁúȯÀº ³ë¾ÈÀ¸·Î, ¾à 8¾ï 2,600¸¸ ¸íÀÌ ¿µÇâÀ» ¹Þ´Â ³ëÈ °ü·Ã ÁúȯÀÔ´Ï´Ù.
½ÃÀ尳ô Áõ°¡
ÇÕº´, Çù¾÷, Á¦Ç° Ãâ½Ã ¹× Àμö¸¦ Æ÷ÇÔÇÑ ½ÃÀå °³¹ßÀÇ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È ±Û·Î¹ú ½ÃÀå ¼ºÀåÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 11¿ù Heidelberg EngineeringÀº ½ÃÇÁÆ® ±â¼ú°ú ÇÔ²² Á¦°øµÇ´Â Spectralis Ç÷§ÆûÀ» °ø°³ÇÏ¿© OCTA ¹× OCTÀÇ »ý»ê¼ºÀ» Çâ»ó½Ã۰í ÀÓ»óÀǰ¡ ´õ ³ªÀº °³ÀÎÈ µÈ Æò°¡¸¦ À§ÇØ OCT ½ºÄµ ¼Óµµ¸¦ Àüȯ ÇÒ ¼ö ÀÖµµ·ÏÇÕ´Ï´Ù. ½ºÆåÆ®¶ö¸®½º Ç÷§ÆûÀº 20kHz, 85kHz, 125kHzÀÇ ¼¼ °¡Áö ½ºÄµ ¼Óµµ¸¦ Á¦°øÇÕ´Ï´Ù.
¶ÇÇÑ 2021³â 7¿ù, Canon Singapore´Â ÇÑ ¹øÀÇ ½ºÄµÀ¸·Î ÃÖ´ë 23¡¿20mmÀÇ °íÇØ»óµµ À̹ÌÁö¸¦ ĸóÇÒ ¼ö ÀÖ´Â Çõ½ÅÀûÀÎ ±¤½Ã¾ß ½ºÀ§ÇÁ ¼Ò½º ±¤ÇÐ Àϰü¼º ÁöÇüµµÀÎ Xephilio OCT-S1À» Ãâ½ÃÇß½À´Ï´Ù. ¶ÇÇÑ 2021³â 6¿ù¿¡´Â Æä¸®¹ÌÅÍ ¸ÞµðÄà À̹Ì¡ AI(Perimeter Medical Imaging AI, Inc.)°¡ ¹Ì³×Æ®·Î´Ð½º ¸ÞµðÄðú ±¤ÇÐ Àϰü¼º ´ÜÃþÃÔ¿µ(OCT) À̹Ì¡ ½Ã½ºÅÛ »ý»êÀ» À§ÇÑ Á¦Á¶ ¹æ¹ý·Ð¿¡ ´ëÇÑ ±â¼ú ÀÌÀüÀ» ÁøÇàÇß½À´Ï´Ù. 2021³â 10¿ù, NIDEKÀº ¾ÈÀú Ä«¸Þ¶ó¿Í OCT°¡ ÅëÇÕµÈ Retina Scan Duo 2¸¦ Ãâ½ÃÇß½À´Ï´Ù. Retina Scan Duo 2´Â ½ºÅ©¸®´× ¹× ÀÓ»ó È¿°ú¸¦ Çâ»ó½Ã۰í ÀÓ»ó ¿öÅ©Ç÷ο츦 °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â Ư¼ºÀ» Á¦°øÇÕ´Ï´Ù.
±¤°£¼·´ÜÃþÃÔ¿µ±â ÀåÄ¡ÀÇ °íºñ¿ë
±¤°£¼·´ÜÃþÃÔ¿µ±â ±â±â ºñ¿ëÀÌ ³ô±â ¶§¹®¿¡ ¼³ºñ ÅõÀÚ°¡ ÀûÀº °³¾÷ÀÇ´Â »õ·Î¿î ±â±â¸¦ ±¸ÀÔÇÒ ¿©À¯°¡ ¾ø°í ´ë½Å Àç»ýǰÀ» »ç¿ëÇϱ⠶§¹®¿¡ ½ÃÀå ¼ºÀåÀÌ µÐ鵃 °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, ZeisÀÇ PRIMUS 200Àº ¾à 19,999 USD, Á¦Á¶»çÀÇ OCT cirrus 5000Àº ¾à 15,999 USD, TopconÀÇ OCT 2000Àº ¾à 7,500 USD, DRI OCT TritonÀº ¾à 12,900 USDÀÔ´Ï´Ù.
±¤°£¼·´ÜÃþÃÔ¿µ±â ±â±â ºñ¿ëÀº ¼³Ä¡µÈ ±â´É¿¡ µû¶ó ´Þ¶óÁý´Ï´Ù. ¿¹¸¦ µé¾î OptovueÀÇ iScan OCT´Â ±âº»ÀûÀÎ ±â´ÉÀ» žÀçÇϰí ÀÖ´Â ÀÌ Á¦Á¶»çÀÇ ivue OCT°¡ ¾à 9,999.00´Þ·¯ÀÎ ¹Ý¸é, °£¼ÒÈµÈ Á¶ÀÛÀ» ½ÇÇöÇÏ´Â °í±Þ ±â´ÉÀ» žÀçÇϰí Àֱ⠶§¹®¿¡ ±âº»ÀûÀÎ ±â´ÉÀ» žÀçÇϰí ÀÖ´Â °Í¿¡ ºñÇØ, °í±Þ ±â´ÉÀ» žÀçÇϰí ÀÖ´Â °ÍÀº ¾à 12,000.00´Þ·¯°¡ µì´Ï´Ù.
¾È°ú Àü¹®ÀÇ ³ëµ¿·Â ºÎÁ·
¾È°ú Àü¹®ÀÇ Àη ºÎÁ·À¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ±Û·Î¹ú ½ÃÀå ¼ºÀåÀÌ µÐ鵃 °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, ¿Õ¸³ ¾È°ú ´ëÇп¡ µû¸£¸é, ´ëºÎºÐÀÇ NHS ¾È°ú ¼ºñ½º´Â »ó´çÇÑ ¿ª·® ½ºÆ®·¹½º¿¡ Á÷¸éÇϰí ÀÖÀ¸¸ç, 4ºÐÀÇ 3 ÀÌ»ó(76%)ÀÇ ÆÀÀÌ ±âÁ¸ ȯÀÚ ¿ä±¸¸¦ ÃæÁ·ÇÒ ¼ö ÀÖ´Â ÀûÀýÇÑ ¼öÀÇ ÄÁ¼³ÅÏÆ®¸¦ È®º¸ÇÏÁö ¸øÇß°í Àý¹Ý ÀÌ»ó(52%)ÀÌ Áö³ 12°³¿ù µ¿¾È ÄÁ¼³ÅÏÆ® ä¿ëÀÌ Ãß°¡·Î ¾î·Á¿ü´Ù°í ´äÇß½À´Ï´Ù.
¶ÇÇÑ 2023³â 1¿ù ¿µ±¹¿¡¼¸¸ ¾È°ú ´ë±âÀÚ ¸í´Ü¿¡ ¿À¸¥ ȯÀÚ´Â 63¸¸ 2,000¸íÀÌ ³Ñ¾úÀ¸¸ç, ÀÌ Áß 2¸¸ 4,000¸íÀº 1³â ÀÌ»ó ´ë±â ÁßÀΠȯÀÚ¿´½À´Ï´Ù. ¾È°ú º´¿øÀÇ ¾à 74%´Â ¿Ü·¡ ȯÀÚ Àûü°¡ 12°³¿ù Àüº¸´Ù ȯÀÚ À¯Áö¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇØ Ãß°¡·Î ¿ì·ÁÇϰí ÀÖÀ¸¸ç, 63%´Â ¿Ü·¡ ȯÀÚ Àûü¸¦ ¿ÏÈÇÏ´Â µ¥ 1³â ÀÌ»ó °É¸± ¼ö ÀÖ´Ù°í Æò°¡Çß½À´Ï´Ù. ¶ÇÇÑ ¿µ±¹ ¾È°ú ÀÇ»çÀÇ 4ºÐÀÇ 1(26%)ÀÌ ÇâÈÄ 5³â ³»¿¡ ÀÌ Á÷¾÷À» ±×¸¸µÑ °èȹÀ̶ó°í ´äÇÏ´Â µî NHSÀÇ ¾È°ú Áø·á Áö¿ø ºÎÁ·À¸·Î ÀÎÇÑ Àη °¨¼Ò°¡ ¿¹»óµË´Ï´Ù.
Global Optical Coherence Tomography Market reached US$ 1.5 billion in 2022 and is expected to reach US$ 2.8 billion by 2030, growing with a CAGR of 8.7% during the forecast period 2023-2030.
Optical coherence tomography utilizes light for the cross-sectional imaging of the tissue arrangement on the micron scale, in situ, and in real time. It is a non-invasive imaging procedure, which is employed to conduct optical biopsies. It is employed in sites where conventional imaging approaches cannot be utilized. OCT is established on fiber optics and can be combined with the tools, like catheters, laparoscopes, endoscopes, and surgical probes, which facilitate imaging of the body.
A significant benefit of OCT over the ophthalmoscopic investigation in vitreoretinal disorder management is the capacity to confine three-dimensional associations between the vitreous, retina, and extraretinal membranes. The applications of OCT enclose the diagnosis of various eye disorders such as the macular hole, macular edema, macular pucker, glaucoma, age-related macular degeneration, central serous retinopathy, vitreous traction, diabetic retinopathy, etc. Presently, OCT is also utilized for the detection and diagnosis of other additional disorders such as cardiovascular diseases, non-melanoma skin cancer, prostate cancer, and age-related macular disease, among other.
The Optical coherence tomography is primarily boosted by the growing cases of opthalmic disorders, increasing market developments including mergers, acquisitions, and product launches among others. Further, the increasing efforts to spread awareness about opthamic disorders and growing cases of other chronic disorders including cardiovascular disorders, non-melanoma skin cancer, prostate cancer, and age-related macular disease, among others are also contributing to the global market growth in the forecast period.
Early detection and monitoring are essential to the diagnosis and management of glaucoma, an advanced optic neuropathy that induces irreversible blindness. Optical coherence tomography (OCT) has evolved into a typically employed imaging modality that assists in the detection and monitoring of structural glaucomatous deterioration. Thus, the high prevalence of diabetic retinopathy is expected to boost the global market growth during the forecast period. For instance, the diabetic retinopathy concerns injury to the eye's retina owing to high blood sugar levels in the blood. It is an expected intricacy of diabetes, impacting millions of individuals with both type 1 and type 2 diabetes.
Further, the growing cases of other ophthalmic disorders are also expected to be contributing to the global market growth in the forecast period. For instance, according to the WHO 2023, globally, at least 2.2 billion individuals are with near or distant vision impairment, and out of these around 1 billion vision impairment could have been averted or is yet to be handled. The top reasons for vision impairment and blindness at a multinational level are refractive disorders and cataracts.
Among these 1 billion individuals, the primary disorders inducing distance eyesight impairment or blindness include cataracts affecting over 94 million individuals, refractive error impacting around 88.4 million people, age-related macular degeneration with over 8 million cases, glaucoma affecting about 7.7 million individuals, and the diabetic retinopathy with over 3.9 million cases. The major disorder inducing near eyesight impairment is presbyopia an age-associated disease with around 826 million individuals impacted.
The increasing number of market developments including, mergers, collaboration, product launches, and takeovers, among others are boosting the global market growth in the forecast period. For instance, in November 2021, Heidelberg Engineering revealed the Spectralis platform, which is provided with shift technology, improves productivity in OCTA and OCT, and also allows clinicians to switch OCT scan pace for a better-personalized assessment. The Spectralis platform delivers three scan rates, 20 kHz, 85 kHz, and 125 kHz.
Moreover, in July 2021, Canon Singapore introduced the Xephilio OCT-S1, an innovative wide-field swept-source optical coherence topography competent for capturing high-resolution images of up to 23×20 mm in a single scan. Also, in June 2021, Perimeter Medical Imaging AI, Inc. conducted the technology transfer of its manufacturing methodology for the production of its optical coherence tomography (OCT) imaging systems with Minnetronix Medical. Again, in October 2021, NIDEK introduced the Retina Scan Duo 2, an integration of a fundus camera and OCT. The Retina Scan Duo 2 is provided with characteristics that enhance screening, and clinical effectiveness, and additionally helps enhance clinical workflow.
The high cost of the optical coherence tomography devices is expected to hamper the global market growth as due to the high cost the practitioners with low capital investments can not afford to buy a new device and instead of which use refurbished ones, slowing the market growth. For instance, the PRIMUS 200 from Zeiss costs around US$ 19,999.00, the OCT cirrus 5000 from the same manufacturer costs about US$ 15,999.00, Topcon OCT 2000 and DRI OCT Triton both from Topocon costs about US$ 7,500.00 and US$ 12,900.00 respectively.
The optical coherence tomography device cost varies based upon the features included the device with advanced features costs more compared to the one with basic features for example iScan OCT from Optovue costs around US$ 12,000.00 as it includes some advanced features which deliver simplified operations while the ivue OCT from the same manufacturer costs about US$ 9,999.00 having basic features.
The shortage of ophthalmologists workforce is expected to slow the global market growth during the forecast period. For instnace, according to the Royal College of Ophthalmologists, the extensive bulk of NHS ophthalmology services are encountering substantial capability stresses, with more than three-quarters (76%) of teams not including an adequate number of consultants to satisfy existing patient needs and more than a half (52%) discovering it is additionally challenging to recruit consultants over the previous 12 months.
Moreover, in January 2023, there were more than 632,000 patients on ophthalmology waiting checklists in England sole and 24,000 of which were waiting for more than a year. Around 74% of eye units are additionally concerned regarding the effect of outpatient backlogs on patient upkeep than they were 12 months back and 63% assess it might take over a year to alleviate their outpatient backlogs. Further, the workforce's lack of NHS eyecare assistance is expected to decline, with a quarter (26%) of ophthalmologists in the UK thinking to exit the workforce over the next five years.
The global optical coherence tomography market is segmented based on product type, volume scan, technology, application, end-user and region.
The oncology application of the OCT is expected to dominate the global market owing to the increasing number of positive outcomes from investigations intended to assess the efficacy of OCT in cancer diagnosis. For instance, in an investigation, investigators corresponded the diagnostic precision of clinical and dermoscopic examination (CDE) with that of CDE integrated with OCT for detecting recurrent or residual BCC post topical therapy of superficial BCC. When utilized in integration with the clinical and dermoscopic study, optical coherence tomography remarkably enhanced the capability to notice recurrent or residual basal cell carcinomas post-topical treatment.
Moreover, in July 2023, a transnational group of investigators improved the procedure of optical coherence tomography (OCT) which carries importance for ophthalmology, dermatology, cardiology, and the early diagnosis of cancer. The work was instructed by the University of Adelaide, Technical University of Denmark (DTU), Aerospace Corp., and the University of St. Andrews.
Also, in August 2022, the Lancet Oncology presented ground-breaking conclusions on Michelson Diagnostics, the UK-based medical device corporation that uses multi-beam Optical Coherence Tomography ('OCT') technology, which can convert patient therapy and maintenance of basal cell carcinomas (BCC). It was inferred that OCT-guided diagnosis, when corresponding to a classic punch biopsy could decrease the number of consultations and invasive approaches by a huge 66%.
The increasing prevalence of ophthalmic disorders in North America is expected to boost regional market growth in the forecast period. For instance, in the United States independently, almost 12 million individuals aged 40 and overhead encountered eyesight impairment, with almost a million suffering from blindness. The CDC notifies that 17.2% of Americans above 40 years of age have a cataract in at least one eye accounting for around 20.5 million individuals. By 2028, above 30 million individuals are expected to suffer from cataracts. The CDC assesses that 4.1 million Americans are impacted with diabetic retinopathy, and almost 900,000 Americans are threatened with vision-damaging retinopathy.
With the growth in life expectancy, diabetes, and other chronic conditions, the cases of eye disorders are anticipated to increase twofold by the year 2050. Age-related macular degeneration (AMD) is the highly expected reason for irreversible eyesight loss in older adults (70 years and older), with an assessed 9 million Americans suffering from intermediate or progressive AMD. Moreover, in 2021, an assessed 9.6 million individuals in the United States, 26% of those having diabetes encountered eye disease, and almost 2 million suffered the most extreme form, "vision-threatening diabetic retinopathy" (VTDR).
Further, the increasing government initiatives to fight against the growing prevalence of eye disorders in the region also contribute to the regional market growth in the forecast period. For instance, in December 2022, congress declared its long-awaited Fiscal Year (FY) 2023 expenditure ruling, which retains a sum of $6.5 million for vision and eye health agendas at the Centers for Disease Control and Prevention (CDC).
In certain, the omnibus spending ruling would sponsor the Vision Health Initiative (VHI) at $2.5 million in FY2023, a $1 million growth over FY2022. The addition would support measures to revise national preponderance assessments on vision impairment and eye disorder. The CDC's Glaucoma project, which supports community-based agendas that unite high-risk patients to eye care, would persist to be sponsored at $4 million.
Presently, ophthalmic practice widely relies on optic coherence tomography (OCT) and optical coherence tomography angiography (OCT-A), which are objective, reliable, and repeatable structural difficulties for both earlier diagnosis and detection of the advancement of various ocular conditions. The missed clinic visits advanced dramatically during the COVID-19 pandemic, particularly among elderly and nonwhite patients. These findings reflect differences in eye care delivery during the pandemic and they indicate possibilities to target barriers to care, even during non-pandemic eras.
However, individuals responded in diverse patterns to COVID-19 conditions. While some individuals produced mild to extreme respiratory issues, others encounter no manifestations at all. Pink eye remained the most typical manifestation of COVID in the eyesight of children and adults. Thus, COVID-19 is estimated to hold intermediate impact over the global market growth in the forecast period.
The Russia Ukraine conflict is expected to have a very little impact over the global market, since the foremost weeks of the attack, Eyes on Ukraine, a humanitarian effort directed by ophthalmologists from across the nation, has been raising funds and shipping medication and surgical supplies to Ukraine ophthalmologists, with multiple reports from hospitals and war crews close to the front that the cargoes are making a general distinction.
Obtaining reserves into the nation, however, has demanded invention and the forging of a trusted network of people, including European ophthalmologists and Polish and Ukrainian mountain defenses, to assure safe transportation of the goods via Poland to Western Ukraine. There, they are distributed by the Ukrainian Vitreoretinal Society to where they are needed considerable. The initiative is believed to be the most active and organized humanitarian help initiatives sustaining eye trauma in the Russian invasion of Ukraine.
The major global players in the market include: Thorlabs, Inc., ZEISS, Topcon Corporation, Leica Microsystems, NIDEK CO., LTD., Heidelberg Engineering Inc., Alcon Inc., Canon Medical Systems, USA., Visionix Ltd. , Abbott, Icare USA, Inc., and OPTOPOL Technology Sp among others.
The global optical coherence tomography market report would provide approximately 61 tables, 58 figures and 186 Pages.
LIST NOT EXHAUSTIVE